CVS Health (NYSE:CVS) Price Target Raised to $111.00

CVS Health (NYSE:CVS) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $101.00 to $111.00 in a research report issued on Tuesday,MarketScreener reports. The firm presently has an “overweight” rating on the pharmacy operator’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 19.99% from the stock’s current price.

Other research analysts have also issued reports about the company. Leerink Partners reiterated an “outperform” rating and issued a $98.00 price objective on shares of CVS Health in a research report on Thursday, March 5th. Royal Bank Of Canada upped their price target on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a research note on Thursday. Bank of America lowered their price target on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, January 27th. Wells Fargo & Company raised their price objective on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, TD Cowen upped their target price on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.00.

CVS Health Price Performance

CVS stock traded up $0.29 during midday trading on Tuesday, reaching $92.51. The stock had a trading volume of 917,495 shares, compared to its average volume of 8,509,286. CVS Health has a 52-week low of $58.35 and a 52-week high of $92.77. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company’s fifty day simple moving average is $77.43 and its 200 day simple moving average is $78.15. The company has a market cap of $118.04 billion, a price-to-earnings ratio of 40.80, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same period in the previous year, the firm posted $2.25 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health will post 7.48 earnings per share for the current fiscal year.

Insider Transactions at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CVS Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Swiss RE Ltd. purchased a new stake in CVS Health during the 4th quarter valued at approximately $26,000. Sankala Group LLC purchased a new position in shares of CVS Health in the 4th quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd increased its stake in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares during the period. Mcguire Capital Advisors Inc. purchased a new position in CVS Health during the fourth quarter worth about $28,000. Finally, Ares Financial Consulting LLC acquired a new stake in CVS Health in the fourth quarter valued at $29,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: TD Cowen raised its price target on CVS Health to $110 from $105 and reiterated a buy rating, reinforcing bullish sentiment after the company’s earnings beat and higher guidance. TD Cowen adjusts price target on CVS Health to 110 from 105
• Positive Sentiment: Recent coverage says CVS looks undervalued, highlighting stronger Q1 revenue, higher EPS, and improving margins and medical benefit trends as signs that the turnaround is gaining traction. CVS Health: Still Cheap And Signs Of Improvement
• Positive Sentiment: CVS also continues to get a lift from broader bullish market commentary, including mentions on CNBC’s “Final Trades” and technical reports saying the stock has broken out after a long consolidation. Nvidia, CVS Health, Vertiv and an energy stock on CNBC’s Final Trades
• Neutral Sentiment: CVS EVP Tilak Mandadi disclosed a sale of 69,551 shares at an average price of $89.58. Insider selling can get attention, but this appears more like a portfolio reduction than a clear fundamental warning. SEC Form 4 filing
• Neutral Sentiment: CVS is also expanding community-care initiatives, including a MinuteClinic partnership in Connecticut and health funding in Missouri, which supports its longer-term strategy but is not an immediate earnings catalyst. CVS Health Expands Community Care Push As Valuation Gap Draws Attention

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.